Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 5/14/2017
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||NM31130 / 2||UN / UN|
Administered by: Other Purchased by: Other
Symptoms: Systemic lupus erythematosus
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? Yes
Hospitalized? Yes, days:
Write-up:Information has been received from Sanofi Pasteur MSD (reference No. IE-1577272925-2015001488) as a part of a business agreement on 28-DEC-2015. This case was received from the RA health authority on 23-DEC-2015 with reference number IE-HPRA-2015-025495. Initial report was received by the RA on 11/Dec/2015 from a member of the public which concerns a 13 year old Female patient who was diagnosed with Systemic lupus erythematosus following vaccination with GARDASIL. Concomitant medications: None. Medical history/concurrent conditions: None. The patient was vaccinated with 3 doses of GARDASIL at a dose of 0.5 ml via IV route between 13/Sep/2010 and 05/Apr/2011. Only one batch/lot number was provided - NM31130 (expiration date was not reported). 7 months post last dose, in Sep/2011, the patient was diagnosed with lupus (SLE). Corrective treatment: Prednisolone, azathioprine and PLAQUENIL. At the time of reporting the patient''s symptoms were ongoing. The patient outcome is not recovered/not resolved.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166